within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD11_MetforminAndLinagliptin;

model MetforminAndLinagliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metformin and linagliptin is a fixed-dose oral antidiabetic combination therapy used in the management of type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that decreases hepatic glucose production and increases insulin sensitivity, while linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin release and suppress glucagon. This combination is approved for use in adults with type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters summarized for healthy adult volunteers after oral administration of a fixed-dose combination tablet (metformin/linagliptin).</p><h4>References</h4><ol><li><p>Koliaki, C, &amp; Doupis, J (2012). Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology. <i>Advances in therapy</i> 29(12) 993–1004. DOI:<a href=\"https://doi.org/10.1007/s12325-012-0067-z\">10.1007/s12325-012-0067-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23184570/\">https://pubmed.ncbi.nlm.nih.gov/23184570</a></p></li><li><p>Deeks, ED (2012). Linagliptin: a review of its use in the management of type 2 diabetes mellitus. <i>Drugs</i> 72(13) 1793–1824. DOI:<a href=\"https://doi.org/10.2165/11209570-000000000-00000\">10.2165/11209570-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22913735/\">https://pubmed.ncbi.nlm.nih.gov/22913735</a></p></li><li><p>Abbas Moussa, B, et al., &amp; Fawzy, MG (2019). A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. <i>Journal of pharmaceutical and biomedical analysis</i> 163 153–161. DOI:<a href=\"https://doi.org/10.1016/j.jpba.2018.09.052\">10.1016/j.jpba.2018.09.052</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30312887/\">https://pubmed.ncbi.nlm.nih.gov/30312887</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndLinagliptin;
